Literature DB >> 11879261

Onset and duration of action of sildenafil for the treatment of erectile dysfunction.

Ian Eardley1, Peter Ellis, Mitradev Boolell, Maria Wulff.   

Abstract

AIMS: To determine the onset and duration of action of sildenafil in patients with erectile dysfunction (ED).
METHODS: Two randomised, double-blind, placebo-controlled, two-way crossover studies were conducted in men with ED of no known organic cause. Study I: The time to onset of erections after sildenafil (50 mg) or placebo dosing following visual sexual stimulation (VSS) was assessed in 17 patients. Patients not achieving >60% penile rigidity by 70 min postdose as measured by a RigiScan(R) monitoring device were assigned an onset time of 70 min. Study II: The duration of grade 3 (hard enough for penetration) and grade 4 (fully hard) erections, determined by self-assessment during 60 min of VSS starting 2 and 4 h after sildenafil (100 mg) or placebo dosing, was measured in 16 patients.
RESULTS: Study I: The median time (range) to onset of erections was 27 min (in a range of 12--70) after receiving sildenafil 50 mg. In the sildenafil group, 71% of patients experienced onset of erections within 30 min of dosing, and 82% responded within 45 min. Of the patients who achieved >60% penile rigidity after sildenafil, 86% had done so by 30 min after dosing. Study II: When VSS began 2 h postdose, the median duration of grade 3 or 4 erections was 19.5 min (0--55) for sildenafil vs 0 min (0--23) for placebo. When VSS began 4 h postdose, the median duration was 5 min (0--45) for sildenafil compared with 0 min for placebo (0--27).
CONCLUSIONS: Sildenafil is an effective oral treatment for ED that produces a penetrative erection as early as 12 min and for most patients, within 30 min after dosing, and a duration of action lasting at least 4 h.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879261      PMCID: PMC1874251          DOI: 10.1046/j.0306-5251.2001.00034.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies.

Authors:  F Montorsi; T E McDermott; R Morgan; A Olsson; A Schultz; H J Kirkeby; I H Osterloh
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

Review 2.  Physiology of penile erection.

Authors:  K E Andersson; G Wagner
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

3.  Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group.

Authors:  F Giuliano; C Hultling; W S El Masry; M D Smith; I H Osterloh; M Orr; M Maytom
Journal:  Ann Neurol       Date:  1999-07       Impact factor: 10.422

4.  Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.

Authors:  C R Conti; C J Pepine; M Sweeney
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

5.  Nitric oxide in the penis: physiology and pathology.

Authors:  A L Burnett
Journal:  J Urol       Date:  1997-01       Impact factor: 7.450

6.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

7.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

8.  Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission.

Authors:  J Rajfer; W J Aronson; P A Bush; F J Dorey; L J Ignarro
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

9.  Evaluation of real-time RigiScan monitoring in pharmacological erection.

Authors:  F G Ogrinc; O I Linet
Journal:  J Urol       Date:  1995-10       Impact factor: 7.450

Review 10.  Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction.

Authors:  L A Levine; E L Lenting
Journal:  Urol Clin North Am       Date:  1995-11       Impact factor: 2.241

View more
  12 in total

1.  Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers.

Authors:  Rosana Gerometta; Lawrence J Alvarez; Oscar A Candia
Journal:  Exp Eye Res       Date:  2011-05-30       Impact factor: 3.467

Review 2.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Animal models in urological disease and sexual dysfunction.

Authors:  Gordon McMurray; James H Casey; Alasdair M Naylor
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Udenafil for the treatment of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

Review 5.  The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.

Authors:  A Zucchi; E Costantini; F I Scroppo; M Silvani; Z Kopa; E Illiano; M G Petrillo; L Cari; G Nocentini
Journal:  Andrology       Date:  2019-07-26       Impact factor: 3.842

6.  Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.

Authors:  Yasmin Chau; Fu-Shuang Li; Olesya Levsh; Jing-Ke Weng
Journal:  PLoS One       Date:  2019-09-20       Impact factor: 3.240

Review 7.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

8.  Evaluation of penile erection rigidity in healthy men using virtual touch tissue quantification.

Authors:  Xiaozhi Zheng; Ping Ji; Hongwei Mao; Jing Wu
Journal:  Radiol Oncol       Date:  2012-01-12       Impact factor: 2.991

Review 9.  Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.

Authors:  Ji Kan Ryu; Kang Su Cho; Su Jin Kim; Kyung Jin Oh; Sung Chul Kam; Kyung Keun Seo; Hong Seok Shin; Soo Woong Kim
Journal:  World J Mens Health       Date:  2013-08-31       Impact factor: 5.400

10.  Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects.

Authors:  Hyounggyoon Yoo; Sang Min Cho; Youn Woong Choi; Hye Jung Lee; Ji-Hye Kwon; Soo-Whan Kim; Jae Woo Kim; SeungHwan Lee; Jang-Hee Hong
Journal:  Transl Clin Pharmacol       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.